Bavarian Nordic（BAVA）株式概要
バイエルン・ノルディックA/S社は、救命ワクチンの開発、製造、供給を行っている。 詳細
BAVA Community Fair Values
Create NarrativeSee what 44 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bavarian Nordic A/S 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | DKK 177.90 |
| 52週高値 | DKK 244.80 |
| 52週安値 | DKK 171.30 |
| ベータ | 0.96 |
| 1ヶ月の変化 | -3.84% |
| 3ヶ月変化 | -5.37% |
| 1年変化 | -24.49% |
| 3年間の変化 | 19.36% |
| 5年間の変化 | -33.62% |
| IPOからの変化 | -30.23% |
最新ニュース
Recent updates
ナラティブ更新 • Jun 15
BAVA: Public Preparedness Contracts Will Support 2026 Earnings Upside
Analysts have kept their DKK 273.33 price target for Bavarian Nordic broadly unchanged, citing only minor adjustments to the discount rate, revenue growth assumptions and future P/E estimates in their valuation work. What's in the News Bavarian Nordic secured a government contract valued at over DKK 700 million to supply its MVA-BN smallpox/mpox vaccine in 2026 and 2027, bringing Public Preparedness business contracts for 2026 to about DKK 2,200 million (Source: company announcement, recent news reports).ナラティブ更新 • Jun 01
BAVA: Public Preparedness Contracts And Vaccine Manufacturing Expansion Will Support 2026 Upside
Analysts have nudged their fair value estimate for Bavarian Nordic higher from DKK 268.33 to DKK 273.33. They point to adjusted assumptions around revenue growth, profit margins and future P/E as the main drivers of the updated price target.
ナラティブ更新 • May 16
BAVA: Public Preparedness Contracts And Vaccine Approvals Will Support Higher Future Returns
Analysts have kept their DKK 280 price target for Bavarian Nordic unchanged, pointing to slightly higher assumed revenue growth and profit margins, along with a modestly higher discount rate and a lower future P/E expectation as key inputs behind the refreshed valuation work. What's in the News Bavarian Nordic raised its earnings guidance for 2026, now expecting revenue of DKK 5,500 million to DKK 5,700 million, compared with the earlier range of DKK 5,000 million to DKK 5,200 million.
ナラティブ更新 • Apr 30
BAVA: Vaccine Approvals And Capacity Expansion Will Drive Future Upside
Analysts have kept their DKK 250.00 price target for Bavarian Nordic unchanged. They point to only small tweaks to assumptions on discount rate, revenue contraction, profit margin and future P/E, which they view as largely offsetting each other.ナラティブ更新 • Apr 16
BAVA: Expanded Vaccine Manufacturing Partnership Will Support 2026 Upside
Analysts have kept their DKK price target for Bavarian Nordic effectively unchanged, with a DKK 0.00 net move. Small tweaks to the discount rate and future P/E assumptions offset each other in their updated valuation work.ナラティブ更新 • Apr 01
BAVA: Expanded Vaccine Pipeline And New Contracts Will Support Higher Future Returns
Analysts have raised their price target on Bavarian Nordic from DKK 244.00 to DKK 280.00. They cite updated assumptions for revenue growth, profit margins, and a lower future P/E multiple that they view as better reflecting the company’s current outlook.ナラティブ更新 • Mar 18
BAVA: Expanded Vaccine Partnerships And 2026 Orders Will Support Upside
Analysts have raised their price target on Bavarian Nordic from DKK 265 to about DKK 268, reflecting adjustments to their valuation inputs, including a slightly higher discount rate, a modest change to revenue growth expectations and a marginally different assumed future P/E and profit margin profile. What's in the News Bavarian Nordic expanded its partnership with Serum Institute of India to include full tech transfer and contract manufacturing for the chikungunya vaccine CHIKV VLP, aiming to scale capacity for future supply to endemic low and middle income countries.ナラティブ更新 • Mar 04
BAVA: Buybacks And Latin America Vaccine Deal Will Drive Future Upside
Analysts have maintained their DKK 250 price target on Bavarian Nordic, citing only minor adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E as the reasons for this stable assessment. What's in the News CEO Paul Chaplin plans to step down for personal reasons, and the Board has agreed that he will stay in the role through the end of 2026 or until a successor is appointed.ナラティブ更新 • Feb 18
BAVA: Share Buybacks And Latin America Vaccine Deal Will Support Upside
Analysts now keep their DKK 250 price target for Bavarian Nordic intact, as slightly higher discount and future P/E assumptions together with a modestly stronger profit margin view offset softer revenue growth expectations. What's in the News Bavarian Nordic issued earnings guidance for fiscal 2026, indicating expected revenue in the range of DKK 5,000 million to DKK 5,200 million (Corporate guidance).ナラティブ更新 • Feb 03
BAVA: Latin America Vaccine Deal Will Support Future Earnings Upside
Analysts have nudged their price target on Bavarian Nordic higher to €265, up from €260, citing updated assumptions on discount rates, revenue expectations, profit margins and forward P/E multiples. What's in the News Bavarian Nordic signed an agreement with Eurofarma, giving Eurofarma exclusive rights to sell and distribute the chikungunya vaccine CHIKV VLP, marketed as VIMKUNYA, in Brazil, along with a right of first refusal for future Latin American opportunities, on a transfer price and royalty basis with no upfront or milestone payments (Key Developments).ナラティブ更新 • Jan 20
BAVA: Vaccine Preparedness Contracts And Buybacks Will Support Stronger Long Term Earnings
Analysts have kept their price target for Bavarian Nordic steady at €250.00. They cite a slightly higher assumed discount rate, a smaller expected revenue decline of around 5%, a higher projected profit margin of about 17%, and a lower future P/E assumption near 23x as key inputs behind the unchanged view.ナラティブ更新 • Jan 06
BAVA: HERA Procurement Contract And Mpox Demand Are Expected To Drive Upside
Analysts have kept their price target for Bavarian Nordic unchanged at €260. This reflects only small tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions rather than a shift in their overall view.ナラティブ更新 • Dec 16
BAVA: Mpox Preparedness Contracts Will Underpin Stronger Long Term Earnings Power
Analysts have raised their price target on Bavarian Nordic from approximately $225 to about $250. This reflects a higher justified valuation multiple despite expectations for softer revenue growth and margins.ナラティブ更新 • Dec 02
BAVA: Procurement Agreement And Margin Outlook Signal Upside For Shares
Analysts have raised their price target for Bavarian Nordic from €250 to €260. They cite improvements in projected profit margins and lower expected future price-to-earnings ratios, even though there is a modest increase in the discount rate and a slightly weaker revenue growth outlook.ナラティブ更新 • Oct 24
Local Spread Of New Mpox Strain Will Challenge Future Vaccine Margins
Narrative Update on Bavarian Nordic Analysts have raised their fair value price target for Bavarian Nordic from €244 to €250, citing modest improvements in valuation assumptions and financial projections. What's in the News Officials in California have confirmed community spread of the new clade 1 Mpox strain among residents with no recent international travel.ナラティブ更新 • Aug 27
VIMKUNYA Launch Will Open Markets, But Approval Delays Could Impact Revenues
Despite a deterioration in consensus revenue growth forecasts, a modest improvement in net profit margin has supported a slight increase in Bavarian Nordic's fair value, with the target price rising from DKK234.50 to DKK244.00. What's in the News Nordic Capital and Permira have proposed to acquire Bavarian Nordic for DKK 18.1 billion (DKK 233 per share), a 21% premium to the prior closing price; board and management have agreed to tender their shares, and a delisting is planned upon completion, subject to customary conditions.分析記事 • Jul 28
Bavarian Nordic A/S (CPH:BAVA) Held Back By Insufficient Growth Even After Shares Climb 38%
Despite an already strong run, Bavarian Nordic A/S ( CPH:BAVA ) shares have been powering on, with a gain of 38% in the...分析記事 • Jun 13
Earnings Working Against Bavarian Nordic A/S' (CPH:BAVA) Share Price
When close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") above 16x, you may consider...分析記事 • Apr 03
Here's Why Shareholders May Want To Be Cautious With Increasing Bavarian Nordic A/S' (CPH:BAVA) CEO Pay Packet
Key Insights Bavarian Nordic's Annual General Meeting to take place on 9th of April Total pay for CEO Paul Chaplin...分析記事 • Mar 13
Bavarian Nordic's (CPH:BAVA) Soft Earnings Are Actually Better Than They Appear
The market for Bavarian Nordic A/S' ( CPH:BAVA ) shares didn't move much after it posted weak earnings recently. We...分析記事 • Mar 08
Bavarian Nordic A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Bavarian Nordic A/S ( CPH:BAVA ) came out with its yearly results last week, and we wanted to see how the business is...
新しいナラティブ • Feb 10
Chikungunya Vaccine Launch And Market Expansion Will Open Opportunities But Mpox Demand Uncertainties Could Pose Risks
The chikungunya vaccine launch and expansion into new markets could significantly drive revenue and broaden customer base.分析記事 • Dec 14
Getting In Cheap On Bavarian Nordic A/S (CPH:BAVA) Is Unlikely
With a median price-to-earnings (or "P/E") ratio of close to 14x in Denmark, you could be forgiven for feeling...分析記事 • Nov 16
Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Aug 26
Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher
Bavarian Nordic A/S ( CPH:BAVA ) shareholders have had their patience rewarded with a 53% share price jump in the last...分析記事 • Aug 25
Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models
Last week, you might have seen that Bavarian Nordic A/S ( CPH:BAVA ) released its quarterly result to the market. The...株主還元
| BAVA | DK Biotechs | DK 市場 | |
|---|---|---|---|
| 7D | 2.0% | -0.08% | -0.7% |
| 1Y | -24.5% | 18.0% | 1.6% |
業界別リターン: BAVA過去 1 年間で18 % の収益を上げたDanish Biotechs業界を下回りました。
リターン対市場: BAVAは、過去 1 年間で1.6 % のリターンを上げたDanish市場を下回りました。
価格変動
| BAVA volatility | |
|---|---|
| BAVA Average Weekly Movement | 3.4% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in DK Market | 7.3% |
| 10% least volatile stocks in DK Market | 2.4% |
安定した株価: BAVA 、 Danish市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: BAVAの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1992 | 1,861 | Paul Chaplin | www.bavarian-nordic.com |
バイエルン・ノルディック社（Bavarian Nordic A/S）は、救命ワクチンの開発、製造、供給を行っている。同社は、IMVAMUNE、IMVANEX、JYNNEOSの名称で非複製天然痘ワクチンとサル痘ワクチン、Rabipur/RabAvertの名称でヒト用狂犬病ワクチン、Encepurの名称でダニ媒介性脳炎ワクチン、コレラ予防接種用経口ワクチンVaxchora、腸チフス予防接種用経口ワクチンVivotif/Typhoralを提供している。また、脳炎ウイルス治療薬MVA-BN WEVも開発中である。米国、デンマーク、カナダ、フランス、ドイツ、シンガポール、フィンランド、オランダ、スイス、スウェーデン、台湾、サウジアラビア、ベルギー、および海外で事業を展開している。バイエルン・ノルディックA/S社は1992年に設立され、本社はデンマークのヘラウップにある。
Bavarian Nordic A/S 基礎のまとめ
| BAVA 基礎統計学 | |
|---|---|
| 時価総額 | DKK 13.58b |
| 収益（TTM） | DKK 1.17b |
| 売上高(TTM) | DKK 5.96b |
11.6x
PER（株価収益率2.3x
P/SレシオBAVA は割高か？
公正価値と評価分析を参照収益と収入
| BAVA 損益計算書（TTM） | |
|---|---|
| 収益 | DKK 5.96b |
| 売上原価 | DKK 3.09b |
| 売上総利益 | DKK 2.87b |
| その他の費用 | DKK 1.69b |
| 収益 | DKK 1.17b |
直近の収益報告
Mar 31, 2026
次回決算日
Aug 21, 2026
| 一株当たり利益（EPS） | 15.37 |
| グロス・マージン | 48.11% |
| 純利益率 | 19.71% |
| 有利子負債／自己資本比率 | 0.1% |
BAVA の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/31 17:52 |
| 終値 | 2026/07/31 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Bavarian Nordic A/S 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14
| アナリスト | 機関 |
|---|---|
| Jacob Lademann | Carnegie Investment Bank AB |
| Peter Verdult | Citigroup Inc |
| Hakon Hemme Jørgensen | Danske Bank |